Martinello Marianne, Naggie Susanna, Rockstroh Juergen Kurt, Matthews Gail V
Kirby Institute, University of New South Wales (UNSW Sydney), Sydney, Australia.
Prince of Wales Hospital, Sydney, Australia.
Clin Infect Dis. 2023 Aug 14;77(Suppl 3):S238-S244. doi: 10.1093/cid/ciad344.
Following the discovery of hepatitis C virus (HCV) in 1989, 3 decades of basic, translational, and clinical research culminated in the development of direct-acting antiviral (DAA) therapy-curative oral treatment for HCV infection. The availability of DAA therapy revolutionized HCV clinical management, including acute (duration of infection <6 mo) and recent (duration of infection <12 mo) infection. Several DAA regimens, including the contemporary pan-genotypic combinations of sofosbuvir-velpatasvir and glecaprevir-pibrentasvir, have been shown to be safe and effective among people with acute and recent HCV infection, highlighting their potential in an HCV controlled human infection model. This article describes the natural history and management of acute and recent HCV infection in the era of DAA therapy and outlines a strategy for use of DAA therapies in the setting of an HCV controlled human infection model.
1989年丙型肝炎病毒（HCV）被发现后，经过30年的基础、转化和临床研究，终于开发出了直接抗病毒（DAA）疗法——一种针对HCV感染的治愈性口服疗法。DAA疗法的出现彻底改变了HCV的临床管理，包括急性感染（感染持续时间<6个月）和近期感染（感染持续时间<12个月）。包括索磷布韦-维帕他韦和格卡瑞韦-哌仑他韦等当代泛基因型组合在内的几种DAA方案，已被证明在急性和近期HCV感染患者中是安全有效的，这凸显了它们在HCV控制的人类感染模型中的潜力。本文描述了DAA疗法时代急性和近期HCV感染的自然史及管理，并概述了在HCV控制的人类感染模型中使用DAA疗法的策略。
